Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Common Equity (2016 - 2025)

Editas Medicine (EDIT) has disclosed Common Equity for 11 consecutive years, with $13.5 million as the latest value for Q3 2025.

  • Quarterly Common Equity fell 92.34% to $13.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $13.5 million through Sep 2025, down 92.34% year-over-year, with the annual reading at $134.3 million for FY2024, 61.54% down from the prior year.
  • Common Equity for Q3 2025 was $13.5 million at Editas Medicine, down from $19.2 million in the prior quarter.
  • The five-year high for Common Equity was $638.0 million in Q1 2021, with the low at $13.5 million in Q3 2025.
  • Average Common Equity over 5 years is $342.3 million, with a median of $360.5 million recorded in 2023.
  • The sharpest move saw Common Equity surged 171.99% in 2021, then tumbled 92.34% in 2025.
  • Over 5 years, Common Equity stood at $553.6 million in 2021, then plummeted by 34.85% to $360.7 million in 2022, then dropped by 3.21% to $349.1 million in 2023, then plummeted by 61.54% to $134.3 million in 2024, then tumbled by 89.98% to $13.5 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $13.5 million, $19.2 million, and $62.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.